
    
      This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose
      study. Thirty-six patients with osteoarthritis of the knee will be selected to participate.
      Patients will be randomized to receive either ABT-981 or placebo. ABT-981 or placebo will be
      administered as subcutaneous (under the skin) injections in four dosing groups. Subjects will
      be administered subcutaneous injections of ABT-981 for up to 8 weeks.
    
  